Edwards Lifesciences Corporation $EW Holdings Boosted by Russell Investments Group Ltd.

Russell Investments Group Ltd. raised its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 4.3% during the 3rd quarter, Holdings Channel.com reports. The firm owned 1,907,920 shares of the medical research company’s stock after acquiring an additional 79,385 shares during the period. Russell Investments Group Ltd.’s holdings in Edwards Lifesciences were worth $148,339,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Schroder Investment Management Group boosted its position in shares of Edwards Lifesciences by 1,657.4% in the third quarter. Schroder Investment Management Group now owns 1,133,475 shares of the medical research company’s stock worth $88,150,000 after buying an additional 1,068,979 shares during the period. Inceptionr LLC purchased a new position in shares of Edwards Lifesciences during the third quarter valued at $1,608,000. Private Advisor Group LLC raised its position in Edwards Lifesciences by 2.0% during the third quarter. Private Advisor Group LLC now owns 23,601 shares of the medical research company’s stock valued at $1,835,000 after buying an additional 463 shares during the period. CreativeOne Wealth LLC raised its position in Edwards Lifesciences by 20.6% during the third quarter. CreativeOne Wealth LLC now owns 3,249 shares of the medical research company’s stock valued at $253,000 after buying an additional 556 shares during the period. Finally, Natixis Advisors LLC lifted its stake in Edwards Lifesciences by 8.7% in the 3rd quarter. Natixis Advisors LLC now owns 257,302 shares of the medical research company’s stock worth $20,010,000 after acquiring an additional 20,574 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 11,340 shares of Edwards Lifesciences stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $85.93, for a total value of $974,446.20. Following the completion of the sale, the vice president owned 21,266 shares of the company’s stock, valued at approximately $1,827,387.38. The trade was a 34.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $85.70, for a total transaction of $87,328.30. Following the completion of the sale, the vice president owned 22,002 shares of the company’s stock, valued at $1,885,571.40. This represents a 4.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 79,144 shares of company stock valued at $6,685,688 over the last ninety days. Corporate insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

EW has been the topic of a number of research reports. UBS Group reiterated a “neutral” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 4th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday, January 21st. Robert W. Baird set a $90.00 target price on shares of Edwards Lifesciences in a research report on Monday, January 12th. Finally, Stifel Nicolaus set a $110.00 target price on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Tuesday, January 20th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average target price of $96.14.

Edwards Lifesciences Stock Down 2.6%

Shares of Edwards Lifesciences stock opened at $81.71 on Monday. The firm has a market cap of $47.46 billion, a price-to-earnings ratio of 44.65, a P/E/G ratio of 2.13 and a beta of 0.93. The stock has a 50-day simple moving average of $82.56 and a 200-day simple moving average of $81.47. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The firm had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The company’s quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, equities research analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.